Cathie Wood buys $37 million of surging tech stock
Cathie Wood, chief of Ark Investment Management, often makes big bets on her target tech stocks. Sometimes, she’ll buy them ...
ARK’s Cathie Wood on Musk, Trump, DeepSeek, and Bitcoin
Valerio Baselli: Hello and welcome to Morningstar. I’m very glad to be joined today by one of the most famous names when it ...
Cathie Wood Goes Bargain Hunting. Here's 1 "Magnificent Seven" Stock She Just Bought on the DeepSeek Dip.
Cathie Wood Goes Bargain Hunting. Here's 1 "Magnificent Seven" Stock She Just Bought on the DeepSeek Dip.
Cathie Wood's ARK ETF adjusts holdings with Deere and Roku trades
Cathie Wood's ARK ETFs have made significant adjustments to their portfolios on Wednesday, February 12, 2025, with a particular focus on Deere & Co (NYSE:DE) and Roku Inc (NASDAQ:ROKU). ARK's largest ...
Crispr Therapeutics price target raised to $86 from $85 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of development in ...
Crispr Therapeutics price target raised to $56 from $55 at Barclays
Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Crispr Therapeutics AG (CRSP) Receives a Hold from Barclays
In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price ...